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Summary  The  aim  of  this  study  was  to  develop  an  artiﬁcial  neural  networks-based  (ANNs)
diagnostic  model  for  coronary  heart  disease  (CHD)  using  a  complex  of  traditional  and  genetic
factors of  this  disease.  The  original  database  for  ANNs  included  clinical,  laboratory,  functional,
coronary  angiographic,  and  genetic  [single  nucleotide  polymorphisms  (SNPs)]  characteristics  of
487 patients  (327  with  CHD  caused  by  coronary  atherosclerosis,  160  without  CHD).  By  changingArtiﬁcial  neural
networks the types  of  ANN  and  the  number  of  input  factors  applied,  we  created  models  that  demonstrated
64—94% accuracy.  The  best  accuracy  was  obtained  with  a  neural  networks  topology  of  multilayer
perceptron  with  two  hidden  layers  for  models  included  by  both  genetic  and  non-genetic  CHD
risk factors.
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he  mortality  rate  caused  by  coronary  heart  disease  (CHD)
as  been  changing  since  the  1990s  and,  in  some  industrial-
zed  countries,  shows  a decline.  However,  morbidity  from
yocardial  infarction  and  angina/CHD  remains  high  in  some
ubgroups,  the  highest  being  male  workers  and  the  elderly
1—6].  It  poses  a  serious  problem,  and  the  development  of
 Published by Elsevier Ltd. All rights reserved.
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methods  for  CHD  prediction  is  of  immediate  scientiﬁc  and
practical  interest.
Several  algorithms  of  risk  stratiﬁcation  and  diagnostic
models  for  CHD  have  already  been  created.  They  are  based
on  different  sets  of  risk  factors,  established  in  epidemiologic
studies  and  randomized  controlled  trials,  such  as  arterial
hypertension,  hypercholesterolemia,  diabetes  mellitus,  and
smoking  [1,7—12]. Some  authors  suggest  using  a  coronary
calcium  score  [13,14]  and  retinal  vascular  signs  [15]  etc.  as
additional  factors.  Recent  developments  focus  on  genetic
markers  for  prediction  of  CHD  and  recommend  including
single  nucleotide  polymorphisms  (SNPs)  for  risk  assessment
[16—19].
It  seems  that  objective  difﬁculties  in  CHD  detection  are
caused  by  the  multiplicity  of  risk  factors  to  be  taken  into
consideration.  This  makes  it  necessary  to  survey  the  struc-
ture  of  the  variable  risk  factors  and  to  create  an  efﬁcient
classiﬁcation  system.  Therefore,  the  development  of  algo-
rithms  for  correct  classiﬁcation  of  CHD  risk  factors  is  an
important  problem.  Nowadays,  computer  methods  of  intel-
ligent  data  processing  are  available  and  applied  for  this
purpose,  and,  on  this  basis,  expert  medical  systems  have
been  created.
One  of  these  promising  methods  is  artiﬁcial  neural  net-
works  (ANNs),  a  highly  effective  tool  used  in  classiﬁcation
tasks,  as  well  as  to  solve  many  important  problems,  such  as
signal  enhancement,  identiﬁcation,  and  prediction  of  signals
and  factors.  The  important  feature  of  ANNs  is  their  adap-
tivity.  This  enables  them  to  be  applied  in  cases  when  it  is
impossible  to  create  a  strict  mathematical  model  but  where
there  is  a  sufﬁciently  representative  set  of  samples.  The
other  important  characteristic  of  neural  networks  is  their
capacity  to  generalize  input  information  and  to  give  correct
answers  for  ‘‘unfamiliar’’  data,  which  makes  them  effec-
tive  in  solving  complicated  classiﬁcation  problems  [20,21].
Today,  ANNs  are  applied  in  clinical  and  genetic  research.
Attempts  have  been  made  to  create  diagnostic  models  for
various  diseases  with  the  use  of  ANNs  of  different  topolo-
gies  [22—25]. It  is  assumed  that  using  complexes  of  signs  of
CHD  will  allow  ANNs  to  not  only  diagnose,  but  also  to  predict
clinically  signiﬁcant  events,  myocardial  infarction  being  the
ﬁrst.
The  aim  of  this  study  was  to  develop  an  ANNs-based  diag-
nostic  model  for  CHD  using  the  complex  of  traditional  and
genetic  factors  of  this  disease.
Materials and methods
The  study  included  487  patients  (males  —  425,  females  —
62,  mean  age:  51.25  ±  9.74  years)  hospitalized  in  Central
Clinical  Hospital  No.  2  of  Russian  Railways  JSC  for  a  coro-
nary  angiography  to  diagnose  CHD.  All  patients  underwent
uniform  standard  clinical  examinations  (laboratory  tests,
electrocardiogram,  Holter  monitoring,  stress  tests,  echocar-
diography  etc.),  coronary  angiography  (Advantx,  General
Electric,  Waukesha,  WI,  USA),  and  genetic  analysis.  The
diagnosis  of  CHD  was  made  following  both  the  clinical  and
coronarography  results.  The  information  obtained  from  test-
ing  and  genotyping  allowed  us  to  create  a  database  of
patients  that  was  subsequently  used  to  diagnose  CHD  using
ANNs.
R
B
C191
isk  factors
HD  risk  factors  included  in  the  analysis  were:  age,
ender,  total  cholesterol,  high-density  lipoprotein  (HDL)
holesterol,  low-density  lipoprotein  (LDL)  cholesterol,  very-
ow-density  lipoprotein  (VLDL)  cholesterol,  triglycerides,
holesterol  ratio,  fasting  plasma  glucose,  arterial  hyper-
ension,  diabetes  mellitus,  current  tobacco  smoking  status,
besity  (Quetelet  index,  body  mass  index  BMI  >  30),  and  a
amily  history  of  CHD.  Additional  factors  taken  into  account
ere  profession  (locomotive  driving),  risk  of  fatal  cardio-
ascular  disease  according  to  the  European  SCORE  project
cale  (SCORE  index)  [1],  left  ventricular  ejection  fraction,
nd  coronary  angiography  data.
enotyping
enotyping  was  performed  by  an  allele-speciﬁc  primer
xtension  of  multiplex  ampliﬁed  products  and  detection
ith  a  matrix-assisted  laser  desorption/ionization  time-of-
ight  mass  spectroscopy  on  an  AutoPhlex  II  MALDI-TOF  MS
Bruker  Daltonics,  Billerica,  MA,  USA).  The  analyzed  panel
ncludes  14  SNPs  localized  in  genes  involved  in  CHD  patho-
enesis:  lipoprotein  lipase  [LIPC  250G/A  (rs2070895)  and
IPC  514C/T  (rs1800588)],  nitric  oxide  synthase  [NOS  E298D
rs1799983)],  methylenetetrahydrofolate  reductase  [MTHFR
223V  (rs1801133)],  angiotensin-converting  enzyme  [ACE
lu  Ins/Del  I>D  (rs4646994)],  angiotensinogen  [AGT  M235T
rs699)],  and  AGT  T174M  (rs4762)  variants,  angiotensin
I  type  1  receptor  [AGTR  A1166C  (rs5186)],  plasminogen
ctivator  inhibitor-1  [PAI-1  5G/4G  (rs1799889)],  and  C-
eactive  protein  [CRP-1  (rs1800947)],  CRP-2  (rs1417938),
RP-3  (rs1205),  CRP-4  (rs3093068),  and  CRP-5  (rs1130864)].
rtiﬁcial  neural  network
he  neural  network  model  was  created  using  a  multilayer
erceptron,  the  multi-level  neural  feedforward  network
aught  by  the  statistical  backpropagation  of  error.  The  sets
f  variable  parameters  were  selected  in  order  to  adjust
NN  models  by  pairwise  correlation  between  the  database
arameters  and  CHD  diagnosis.
Accuracy  of  models  was  improved  by  a  genetic  algo-
ithm  with  different  optimization  parameters  [26]  including
umber  of  neurons  in  the  hidden  layer,  number  of  inputs
o  the  neural  network,  and  slope  coefﬁcient  of  activation
unctions.  NeuroSolutions  5.0  development  environment
NeuroDimension  Inc.,  Gainesville,  FL,  USA)  was  used  to
heck  the  possibilities  of  optimization.
The  ANN  was  created  by  inputting  the  speciﬁed  variable
actors.  The  task  to  solve  was  of  two-class  classiﬁcation:
‘1’’  — CHD,  ‘‘0’’  — healthy.  A  total  of  287  examples  were
sed  for  teaching,  100  for  cross-validation,  and  100  for  test-
ng.esults
ased  on  the  results  of  the  clinical  instrumental  research,
HD  caused  by  coronary  atherosclerosis  was  diagnosed  in
192  O.Yu.  Atkov  et  al.
Table  1  Accuracy  of  ANN  models  for  CHD  diagnosis.a
Model  Factors  Accuracy  (%)
I  Age,  profession,  diabetes,  arterial  hypertension,  smoking,  obesity,  family  anamnesis  of
CHD, glucose,  cholesterol
64
II Age,  profession,  diabetes,  arterial  hypertension,  smoking,  obesity,  family  anamnesis  of
CHD, glucose,  cholesterol
77
III Age,  profession,  diabetes,  arterial  hypertension,  smoking,  obesity,  family  anamnesis  of
CHD, glucose,  total  cholesterol,  HDL,  LDL,  VLDL,  triglycerides,  cholesterol  ratio
83
IV Age, profession,  diabetes,  arterial  hypertension,  smoking,  obesity,  heredity,  glucose,
total cholesterol,  HDL,  LDL,  VLDL,  triglycerides,  cholesterol  ratio,  coronary  angiography
data
91
V NOS,  ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs  90
VI NOS,  ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs,  SCORE  index  83
VII NOS, ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs,  coronary  angiography
data
89
VIII NOS,  ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs,  SCORE  index,  coronary
angiography  data
93
IX NOS,  ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs,  HDL,  LDL,  glucose  90
X NOS,  ACE, AGT-235,  AGT-174,  AGTR,  CRP-1,  CRP-2,  CRP-3  SNPs,  age,  smoking,  obesity,
family anamnesis  of  CHD,  HDL,  LDL
88
CHD, coronary heart disease; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; VLDL, very-low-density
lipoprotein cholesterol; SNP, single nucleotide polymorphisms.
a In all cases, the multilayer perceptron neuronal network topology with two buried 4-neuron layers was used.
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t27  (67.2%)  patients.  A  total  of  160  (32.8%)  patients  had  an
ntact  coronary  artery  wall  and  no  evidence  of  CHD.
Correlation  analysis  between  the  speciﬁed  variable  fac-
ors  and  CHD  allowed  us  to  choose  32  factors  associated  with
he  disease.  These  factors  were  analyzed  by  ANNs.
Approaches  using  different  ANN  types  and  a  variable
umber  of  input  factors  (from  5  to  10)  led  to  the  mod-
ls  with  64—94%  diagnostic  accuracy.  The  best  result  (94%)
as  achieved  in  a  multilayer  perceptron  (MLP)  model  with
wo  buried  layers  and  10  factors  (profession,  LDL,  HDL,
riglycerides,  cholesterol  rate,  SCORE  index,  left  ventricular
jection  fraction,  family  CHD  history,  coronary  arteriogra-
hy  data,  PAI  gene).  On  the  other  hand,  the  same  ANN
ype  with  5  factors  (coronary  arteriography  data,  choles-
erol  rate,  SCORE  index,  left  ventricular  ejection  fraction,
AI  gene)  had  a  lower  diagnostic  accuracy  (78%).  How-
ver,  the  same  10  factors  analyzed  by  other  ANN  types
ielded  a  79%  result.  This  suggests  that  the  diagnostic  accu-
acy  depends  on  the  ANN  type  and  the  number  of  variable
actors.
The  next  step  included  an  analysis  of  10  models  of  CHD
rediction  formed  by  different  combinations  of  examination
locks  (demographic  characteristics,  CHD  history,  laboratory
ests,  echocardiography  and  coronary  angiography  data,
enes)  by  the  MLP  with  two  buried  4-neuron  layers.  The  num-
er  of  variable  input  factors  ranged  from  8  (models  I  and  V)
o  15  (model  IV).  The  results  are  shown  in  Table  1.  The  mini-
al  accuracy  of  64%  was  obtained  in  model  I,  which  included
 non-genetic  factors.  Models  IV,  V,  VIII,  and  IX,  which  had
igniﬁcantly  different  sets  of  variables,  showed  ≥90%  diag-
ostic  accuracy.  Model  IV  included  only  non-genetic  factors;
odel  V  included  only  eight  SNPs  (NOS, ACE, AGT-235,  AGT-
74, AGTR, CRP-1, CRP-2  and  CRP-3); model  VIII  included  the
l
a
o
eame  SNPs  in  combination  with  coronary  angiography  data
nd  SCORE  index;  model  IX  included  the  same  SNPs  and  HDL,
DL,  and  glucose.  Thereby  the  optimal  accuracy  was  more
ften  achieved  when  a  diagnostic  model  included  genetic
actors.
iscussion
ne  of  the  modern  approaches  to  the  solution  of  classi-
cation  problems  is  intelligent  data  processing  based  on
esolving  optimization  tasks  using  ANNs.  Our  results  suggest
hat  ANNs  may  also  be  used  to  create  a  highly  accurate  and
ffective  model  for  CHD  prediction.
In  this  research  we  have  examined  the  inﬂuence  of  dif-
erent  parameters,  teaching  methods,  and  neural  network
opologies  on  the  accuracy  of  CHD  diagnosis.  We  revealed
hat  the  optimal  topology  to  resolve  this  classiﬁcation  task
s  a  MLP  with  two  buried  layers.  The  optimal  input  parame-
ers  are  8—10  of  the  most  signiﬁcant  factors:  the  use  of  all
actors  seems  to  excessively  complicate  the  model,  while,
t  the  same  time,  smaller  numbers  do  not  provide  essential
nformation  for  resolving  this  problem.  It  is  of  interest  to
ote  that,  in  some  models,  the  accuracy  of  CHD  diagnosis
as  lower  than  90%  in  spite  of  including  coronary  arteriog-
aphy  data,  which  are  considered  the  ‘‘gold  standard’’  for
HD  diagnosis  in  clinical  practice.
Publications  on  the  possibilities  of  cardiologic  applica-
ion  of  artiﬁcial  intelligence,  ANN,  ﬁrst  of  all,  are  usually
imited  to  different  combinations  of  traditional  laboratory
nd  instrumental  methods  [22—25]. Therefore,  the  novelty
f  our  study  is  the  inclusion  of  genes  as  risk  factors  in  order  to
stimate  capabilities  of  CHD  prediction.  In  this  connection,
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[
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[
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it  is  important  to  note  that  the  accuracy  of  the  diagnosis
based  on  genetic  factors  only  was  found  to  be  almost  equal
to  that  in  the  model  combining  15  non-genetic  factors  (90%
and  91%,  respectively).  The  most  informative  (93%)  was  the
model  that  included  8  SNPs,  SCORE  index,  and  coronary  arte-
riography  data.  Taking  into  account  the  fact  that  genetic
information  is  a  permanent  parameter,  it  can  be  assumed
that  analysis  of  NOS, ACE, AGT-3, AGT-4, AGTR, CRP-1, CRP-
2,  and  CRP-3  SNPs  enables  prediction  of  CHD  with  a high
accuracy.
The  diagnostic  accuracy  can  be  improved  not  only  by
increasing  the  number  of  genetic  markers,  but  also  by  their
precise  selection.  Good  candidates  for  consideration  may
be  genes  involved  in  vascular  cell  growth,  apoptosis,  and
inﬂammation,  or  others  associated  with  CHD,  e.g.  ABCA1
(ATP-binding  cassette-transporter  A1),  CYP1A2  (cytochrome
P450),  ADRB  group  (-adrenoreceptors),  HSF1  (heat  shock
factors)  [27], CLOCK, and  BMAL1  [28]. The  last  ones  are
of  interest  because  they  are  associated  with  the  regulation
of  circadian  rhythms,  including  those  in  the  cardiovascular
system  [29].
The  obtained  experience  in  the  development  of  neural
network  models  for  CHD  prediction  constitutes  a  basis  for
the  design  of  applied  software  products  for  the  diagnosis  of
cardiovascular  diseases,  including  screening  tests.
Conclusion
The  purpose  of  this  study  was  to  create  CHD  diagnos-
tic  models  with  appropriate  analytical  characteristics  using
MLP  ANNs.  The  best  accuracy  was  obtained  in  models  that
included  both  genetic  and  non-genetic  factors  associated
with  the  disease.  The  models  of  >90%  accuracy  may  serve  as
the  basis  for  the  development  of  software  tools  for  diagnosis
and  prediction  of  CHD.
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